Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04274153
Other study ID # IRB00227941
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date August 3, 2020
Est. completion date February 1, 2023

Study information

Verified date August 2023
Source Johns Hopkins University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The human papillomavirus (HPV) is the most common sexually transmitted infection (STI) in the United States (U.S.) and is responsible for a wide range of conditions, including cancers within the anogenital tract and the oropharynx. In just the U.S. alone, it's estimated that HPV causes 330,000 cases of precancerous cervical dysplasia and 12,000 cases of cervical cancer. The investigators propose a 2-dose HPV vaccination study in women seeking postpartum care at Johns Hopkins University. The investigators will measure the immunogenicity and acceptability of the vaccine in the postpartum setting.


Description:

This is a pilot, non-inferiority clinical trial using historical controls. Participants will have whole blood drawn at 0 months, 6 months, and 7 months and receive the HPV vaccine at 0 months, 6 months, and 12 months. Each blood draw will consist of one 15mL red top tube to measure HPV serologies and hormone levels. All blood samples collected will be analyzed at the end of the study.


Recruitment information / eligibility

Status Completed
Enrollment 225
Est. completion date February 1, 2023
Est. primary completion date July 1, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 15 Years to 45 Years
Eligibility Inclusion Criteria: - Participants biologically born as females between the ages of 15 through 45 who have delivered a live born baby within the past 72 hours. Exclusion Criteria: - Pregnancy - Severe allergic reaction to vaccine components - Prior receipt of an HPV vaccine dose - Fetal demise or stillbirth - Allergy to latex or yeast - Moderate or severe acute illness (deemed by the investigator to exclude) - Immunosuppression (e.g., HIV, solid organ transplant).

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Gardasil9
Two doses of the HPV vaccine across a 12 month period (two doses of 0.5mL).

Locations

Country Name City State
United States Johns Hopkins Bayview Medical Center Baltimore Maryland
United States Johns Hopkins University Baltimore Maryland

Sponsors (2)

Lead Sponsor Collaborator
Johns Hopkins University Merck Sharp & Dohme LLC

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Immunogenicity of a Two-dose 9-valent HPV Vaccination as Assessed by Antibody Titer Measure the immunogenicity of a two-dose 9-valent HPV vaccination regimen in postpartum women previously unvaccinated against the HPV 16 virus. Immunogenicity will be assessed by the antibody responses. The Geometric mean titers will be measured using milli Merck units (mMU)/mL. Up to 23 months
Secondary Antibody Response to the Other 8 HPV Types The antibody types that will be measured are HPV types 6, 11, 18, 31, 33, 45, 52, and 58.
The milli Merck units (mMU)/mL of measure will be used to determine antibody response.
Up to 23 months
Secondary Seropositivity for HPV 16 After 1-dose Calculate the percentage of participants that seroconverted. After the first dose, up to 7 months
Secondary Seropositivity for HPV 16 After 2-doses Calculate the percentage of participants that seroconverted. After the second dose, up to 2 months
Secondary Percentage of Participants With Baseline Titers Suggestive of Natural Inoculation or Prior Vaccination to HPV 16 Running an assay to measure a participants natural inoculation or prior vaccination before administration of the 1st dose. Baseline
Secondary Percentage of Participants Who Complete 2-dose Vaccination Calculate the amount of participants that complete 2-dose vaccination. At the end of the study, up to 2 years
See also
  Status Clinical Trial Phase
Recruiting NCT05329961 - Immunogenicity of the 9vHPV Vaccination 2-dose Regimen Among Children 4 to 8 Years Old, An Exploratory Immunogenicity Study Early Phase 1
Completed NCT05862844 - Promise Women Project N/A
Active, not recruiting NCT04199078 - Clinical Trial to Explore Papilocare Gel Efficacy to Repair of the Cervico-vaginal Mucosa With HPV High Risk Lesions. N/A
Recruiting NCT05566106 - Anal Follow-up of Patients With a Gynecological History of High-grade Lesion and More Induced HPV
Not yet recruiting NCT06229353 - Developing and Evaluating a Novel Approach to Improve HPV Vaccination Coverage Among High-risk, Under-immunized Adults Via the Emergency Department
Completed NCT01757392 - Candin Safety & Efficacy Study for the Treatment of Warts Phase 2
Active, not recruiting NCT04716127 - A Proximity-incentive Strategy for Cervical Cancer Screening N/A
Recruiting NCT05210348 - Clinical Evaluation of Detection of High Risk HPV in Urine
Recruiting NCT05835947 - Anal Cancer Risk In Women
Not yet recruiting NCT03947775 - HPV-SAVE_Merck_Sub-Study for Preventing Recurrence of HSIL Phase 2
Terminated NCT03404310 - Zinc Sulfate for Human Papillomavirus (HPV) N/A
Recruiting NCT03302858 - A Safety and Efficacy Trial of Circumferential Anal Canal Radiofrequency Ablation for High-Grade Anal Intraepithelial Neoplasia Using the BARRXâ„¢ Anorectal Wand Phase 2
Completed NCT03082950 - HPV Infections, Cancer of the Vulva and Therapeutical Success
Recruiting NCT04950101 - Prevalence of Anal High-risk Human Papilloma Virus Infection and Abnormal Anal Cytology in Men Who Have Sex With Men Using Pre Exposure Prophylaxis N/A
Recruiting NCT05146895 - A Cohort Study of Hyperthermia and Imiquimod for the Treatment of Flat Warts N/A
Completed NCT04002154 - Clinical Trial to Explore the Papilocare Gel Efficacy to Repair the Cervico-vaginal Mucosa With Lesions Caused by HPV N/A
Recruiting NCT04232917 - Study of 2LPAPI® on the Clearance of Genital HR-HPV Infections. Phase 4
Active, not recruiting NCT03729518 - TORS De-Intensification Protocol Version 2.0: Dose and Volume Reduction in the Neck N/A
Recruiting NCT05640700 - Vaginal Microbiome and HPV Pre-malignant and Cervical Dysplasia
Recruiting NCT05362669 - SMS Messaging for Invitation in the Cervical Cancer Screening Programme N/A